A Divesture To Kick Up Valuation For Genzyme Drives U.S. Expansion For Japanese Diagnostic Firm
This article was originally published in The Pink Sheet Daily
Executive Summary
Sale is the second of three units Genzyme said it would divest to generate shareholder value, but which is seen largely as a move to enhance valuation as it courts buyers.